Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 5Fluorouracil, 5-fluorouracil
5- Fluorouracil · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cetuximab and Cisplatin (D) | EXPERIMENTAL | Cycle 1 (1 week, combination therapy): 400 milligrams per square meter (mg/m²) cetuximab administered (admin) intravenously (I.V) on week 1, day 1. 100 mg/m² cisplatin administered I.V on week 1, day 1. Optional 5- fluorouracil (FU) administered as a 96-hour continuous infusion (C.I.) of 1000 mg/m²/day (d) administered starting on week 1, day 1. After 1 cycle, participants may continue treatment as determined by the physician until progression of disease, unacceptable toxicity, or another withdrawal criterion is met. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only. |
| Cetuximab and Cisplatin (C) | EXPERIMENTAL | Cycle 1 (4 weeks, combination therapy): 100 mg/m² Cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1. 400 mg/m² cetuximab admin I.V on week 2, day 1. 250 mg/m² cetuximab admin I.V on week 3 and 4, day 1. Cycle 2-6 (3 weeks combination therapy): 100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1. 250 mg/m² cetuximab admin I.V on week 1, 2, and 3, day 1. After 6 cycles, participants may then receive weekly cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met. Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only. |
| Cetuximab on Cisplatin (B) | EXPERIMENTAL | Cycle 1: 400 mg/m² cetuximab admin I.V on week 1, day 1. 250 mg/m² cetuximab admin I.V on week 2 and 3, day 1. Cycle 2: 100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1- 4. 250 mg/m² cetuximab admin I.V on week 1-3, day 1. Cycle 3 + : 100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4. 250 mg/m² cetuximab admin I.V on week 1-3, day 1. After 6 cycles, participants may then receive weekly cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met. Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only. |
| Cisplatin on Cetuximab (A) | EXPERIMENTAL | Cycle 1: 100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4. 400 mg/m² cetuximab admin I.V on week 2, day 1. 250 mg/m² cetuximab admin I.V on week 3, day 1. Cycle 2 +: 100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4. 250 mg/m² cetuximab admin I.V on weeks 1-3, day 1. After 7 cycles, participants may then receive weekly Cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met. Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only. |
| Name | Type | Description |
|---|---|---|
| Cetuximab | DRUG | Administered Intravenously |
| Cisplatin | DRUG | Administered Intravenously |
| 5 - Fluorouracil | DRUG | Administered Intravenously |
Inclusion Criteria: * The participant has histologically or cytologically advanced solid tumor that is resistant to standard therapy or for which there is no standard therapy. * The participant has measurable or non-measurable disease. * The participant has a life expectancy of greater than 3 month...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
5-Fluorouracil is a small molecule oncology drug being studied for use in solid tumors, colorectal cancer, and head and neck cancer. It is currently in Phase 2 clinical development as an investigational therapy. The drug is being developed by Eli Lilly and Company.
Eli Lilly and Company (NYSE: LLY) is the developer of 5-Fluorouracil. The company is conducting clinical trials of the drug in oncology indications including colorectal cancer, head and neck cancer, and solid tumors.
5-Fluorouracil is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials have been completed in colorectal cancer, head and neck cancer, and solid tumors.
5-Fluorouracil has been studied in three completed clinical trials. NCT00061815 was a Phase 3 study in colorectal cancer with 102 participants. NCT01081041 was a Phase 2 study in head and neck cancer with 187 participants. NCT01099358 was a Phase 2 study in advanced solid tumors with 47 participants.
Yes, 5-Fluorouracil is also known as 5Fluorouracil and 5-fluorouracil. These names refer to the same drug being developed by Eli Lilly and Company for oncology indications.